A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Study identification

NCT ID

NCT06215716

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Akero Therapeutics, Inc

Industry

Enrollment

1,650 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 80 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Nov 30, 2023

Primary completion

Jan 31, 2033

Completion

Jan 31, 2033

Last update posted

Aug 6, 2026

2023 – 2033

United States locations

U.S. sites

200

U.S. states

34

U.S. cities

163

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.